CorMedix Q3 2024 Earnings Report

CorMedix reported Q3 2024 financial results with net revenue of $11.5 million.

Key Takeaways

CorMedix reported net revenue of $11.5 million for the third quarter of 2024, marking the first full quarter of sales since DefenCath was launched. The company's net loss decreased by 72% compared to the same period last year, driven by DefenCath sales. Operating expenses increased due to higher selling and marketing and general and administrative expenses.

Net revenue for Q3 2024 was $11.5 million from DefenCath sales.

Net loss for Q3 2024 was $2.8 million, a 72% decrease compared to Q3 2023.

Operating expenses increased by 34% in Q3 2024, driven by higher selling and marketing and general and administrative expenses.

Cash and short-term investments were $46.0 million as of September 30, 2024.

Previous year: -$0.17

-70.6%

Gross Profit